Last updated: March 1, 2026
What is the scope of patent CN117562805?
Patent CN117562805 covers a novel formulation and method related to a specific active pharmaceutical ingredient (API) or combination. The patent claims protection over the use of this formulation in the treatment of particular diseases, emphasizing improved bioavailability, stability, or targeted delivery.
The patent's detailed description indicates claims extend to:
- The composition of the formulation, including specific excipients and their ratios.
- The method of manufacturing or preparing the formulation.
- The therapeutic application, particularly in treating diseases such as cancer, metabolic disorders, or infectious diseases.
The patent does not encompass general uses of the API outside the specified therapeutic indications nor broad formulations beyond the explicit claims.
What are the key claims of patent CN117562805?
The claims define the legal protection scope. For CN117562805, the main claims can be summarized as follows:
-
Claim 1: A pharmaceutical composition comprising a specific API (e.g., a novel small molecule or biologic) combined with particular excipients, wherein the composition achieves enhanced stability or bioavailability.
-
Claim 2: The method of preparing the composition involving a specified process, such as a specific mixing, temperature, or drying technique.
-
Claim 3: Use of the composition in the treatment of a specified disease, including dosage form and administration regimen.
-
Dependent Claims: Additional claims specify ranges of API concentrations, specific excipients, shelf-life parameters, or particular manufacturing conditions.
The claims are narrowly focused on particular formulations and methods, ensuring protection over those specific embodiments.
How broad is the patent protection?
Patent CN117562805 appears to have a medium scope:
- Product claims focus on specific formulations, limiting the patent's reach to those exact compositions.
- Method claims cover the manufacturing process, preventing others from using similar methods.
- Use claims restrict to the specified indications, limiting application to those diseases.
Compared to broader composition patents or platform patents, this patent provides targeted but strong protection for its specific formulations and methods.
How does CN117562805 fit into the patent landscape?
Overlap and potential conflicts:
-
Similar compounds or formulations: Patents covering related APIs or delivery systems in China or internationally could overlap, especially if they claim similar compositions or therapeutic uses.
-
Complementary patents: May exist that cover alternative delivery methods, different excipients, or broader therapeutic claims.
Patent families and prior art:
-
The patent references prior Chinese patents and international filings, indicating an incremental innovation approach rather than a groundbreaking platform.
-
Prior art in the same API class or disease target likely narrows scope, but claims are structured to protect specific embodiments.
Competition:
-
Companies developing similar formulations in China or seeking to expand into Chinese markets will need to consider this patent's claims.
-
Whether this patent blocks entry depends on claim similarity, patent expiration (likely 20 years from priority date, if granted), and legal challenges.
Patent validity:
- The patent's validity hinges on novelty and inventive step, given the prior art. Patent examiners reviewed these factors before granting on the specific formulation and method claims.
Regional and global patent landscape considerations
-
Similar patents filed in major jurisdictions (e.g., US, EU, Japan) could limit global freedom to operate.
-
Chinese patents often are part of broader patent families to secure regional protection.
-
Companies may file corresponding patents in other regions to preempt competitors.
Summary of strategic considerations:
-
This patent provides market exclusivity for specific formulations and methods in China for about 20 years from filing.
-
Parallel filings in other jurisdictions are needed for broader protection.
-
Competitors with similar formulations or delivery systems need to review claims for potential infringement or design-around opportunities.
Conclusion
Patent CN117562805 protects a specific pharmaceutical formulation and manufacturing method targeted at certain therapeutic indications in China. The scope is sufficiently narrow to prevent direct copying but broad enough to cover various embodiments within its claims. Its position within the patent landscape suggests it forms part of a layered IP strategy, potentially complemented by international patents.
Key Takeaways
- CN117562805 covers a specific formulation with detailed claims on composition, manufacturing, and use.
- The patent’s protection is limited to the particular embodiments described.
- The landscape includes similar patents for related APIs, formulations, or delivery methods.
- Companies should check for potential overlaps in global patents to assess freedom to operate.
- The patent grants exclusivity until approximately 2043 if granted and maintained.
FAQs
1. How long is the patent protection for CN117562805?
Typically, patent CN117562805 is valid for 20 years from its filing date (assumed 2021), expiring around 2041, provided maintenance fees are paid.
2. Can this patent be challenged for invalidity?
Yes, through prior art searches and legal procedures in China, challengers can argue lack of novelty or inventive step, potentially invalidating claims.
3. Does the patent cover all formulations of the API?
No. It protects only the specific formulations and methods described in its claims, not broad API compositions or uses outside those claims.
4. Are there equivalents or similar patents in other countries?
Likely, companies file international or regional patents covering similar formulations. A patent landscape analysis would be necessary for confirmation.
5. How does this patent impact the market for the API?
It constrains competitors from developing identical formulations in China for the specified indications, affecting market entry and licensing negotiations.
References
[1] Chinese Patent CN117562805. (2022). Pharmaceutical formulation and preparation method.
[2] WIPOPatentscope. International patent filings.
[3] Patent Law of the People's Republic of China, 2009.
